News
- Author:
- Neil Osterweil
Publish date: August 12, 2019
LUGANO, SWITZERLAND –The chemotherapy-free combination was associated with a high objective response rate in patients with a median age of 71 years...
News
- Author:
- Neil Osterweil
Publish date: August 9, 2019
LUGANO, SWITZERLAND – Patients with AITL and PTCL-TFH subtypes had high overall response rates to romidepsin and AZA.
News
- Author:
- Neil Osterweil
Publish date: August 7, 2019
The combination of bevacizumab and pemetrexed did not improve survival and had significantly worse toxicity than bevacizumab alone.
News
- Author:
- Neil Osterweil
Publish date: August 6, 2019
Women with high EPclin scores would be likely to have an absolute benefit from chemotherapy added to endocrine therapy, a mathematical model predic...
News
- Author:
- Neil Osterweil
Publish date: August 1, 2019
Circulating tumor DNA was associated with a significant risk for relapse in women treated for early primary breast cancers.
News
- Author:
- Neil Osterweil
Publish date: July 26, 2019
Tumor mutational burden in non–small cell lung cancer varies according to histology and tumor sample location.
News
- Author:
- Neil Osterweil
Publish date: July 25, 2019
Survivors of childhood non-Hodgkin may be at significantly increased risk for breast, ovarian, prostate, and other BRCA2-associated cancers.
News
- Author:
- Neil Osterweil
Publish date: July 25, 2019
Absence of bone or liver metastases and excellent baseline performance status are linked to 5-year OS in melanoma, RCC, and NSCLC treated with nivo...
News
- Author:
- Neil Osterweil
Publish date: July 23, 2019
LUGANO, SWITZERLAND – Lenalidomide plus the anti-CD19 antibody tafasitamab was associated with a 60% overall response rate.
News
- Author:
- Neil Osterweil
Publish date: July 15, 2019
LUGANO, SWITZERLAND – Adding lenalidomide to R-CHOP reduced the risk of diffuse large B-cell lymphoma progression or death by 34% in the ECOG-ACRIN...
News
- Author:
- Neil Osterweil
Publish date: July 11, 2019
AMSTERDAM – Monotherapy with the Bruton tyrosine kinase inhibitor acalabrutinib offered better progression-free survival, compared with rituximab-b...
News
- Author:
- Neil Osterweil
Publish date: July 10, 2019
AMSTERDAM – The Bruton’s tyrosine kinase inhibitor was associated with a halving of risk for death, compared with chlorambucil.
News
- Author:
- Neil Osterweil
Publish date: July 10, 2019
LUGANO, SWITZERLAND – The ROBUST trial is the latest in a long line of studies that failed to show improvement in outcomes with the addition of a n...
News
- Author:
- Neil Osterweil
Publish date: July 5, 2019
AMSTERDAM – Rituximab maintenance was no better than observation for patients in first complete remission after induction chemotherapy with R-CHOP....
News
- Author:
- Neil Osterweil
Publish date: June 25, 2019
AMSTERDAM – Patients who had genomic evidence of a lingering AML variant had worse posttransplant outcomes when they underwent reduced-intensity co...
